37  -3.83 (-9.38%)		12-05 16:00
Open: 42.28 High: 44.73 Volume: 48,472		Pre. Close: 40.83 Low: 37 Market Cap: 1,624(M)

Short term
Mid term
Targets	6-month :	52.24	1-year :	61.02
Resists	First :	44.72	Second :	52.24
Pivot price	27.76
Supports	First :	23.57	Second :	10.5
MAs	MA(5) :	33.36	MA(20) :	25.99
	MA(100) :	36.04	MA(250) :	0
MACD	MACD :	2.4	Signal :	0.5
%K %D	K(14,3) :	77.6	D(3) :	73.9
RSI	RSI(14): 64.2
52-week	High :	55.65	Low :	5.32

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NNNN ] has closed below upper band by 6.3%. Bollinger Bands are 48.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	44.77 - 44.99	44.99 - 45.14
Low:	36.54 - 36.8	36.8 - 36.96
Close:	36.64 - 37.02	37.02 - 37.26

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Thu, 20 Feb 2025
Anbio Biotechnology Closes Initial Public Offering, Raising $8 Million on Nasdaq - Nasdaq

Thu, 20 Feb 2025
Anbio Biotechnology prices $8M IPO at $5 per share - MSN

Tue, 18 Feb 2025
NNNN Stock Price and Chart — NASDAQ:NNNN - TradingView

Thu, 02 Jan 2025
Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha

Sun, 07 Dec 2025

Sun, 07 Dec 2025

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	44 (M)
Shares Float	40 (M)
Held by Insiders	4.7 (%)
Held by Institutions	4.9 (%)
Shares Short	67 (K)
Shares Short P.Month	124 (K)

EPS	0.05
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.4
Profit Margin	28.9 %
Operating Margin	-68.7 %
Return on Assets (ttm)	7.1 %
Return on Equity (ttm)	14.8 %
Qtrly Rev. Growth	-36.1 %
Gross Profit (p.s.)	0.13
Sales Per Share	0.18
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	2 (M)
Levered Free Cash Flow	1 (M)

PE Ratio	740
PEG Ratio	0
Price to Book value	90.24
Price to Sales	198.28
Price to Cash Flow	780.73

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.